Quick Answer: Retatrutide Side Effects
The most common retatrutide side effects are gastrointestinal: in the Phase 2 trial's posted results, nausea affected 45% of the 12 mg group (and up to 60% in the 8 mg group that started at 4 mg), vomiting up to 26% and diarrhea up to 20% depending on dose and starting dose. Retatrutide has no FDA label, so these are trial data. Most GI symptoms peak during the first 4–8 weeks and improve as the body adjusts. Serious side effects are rare. Slow titration (increasing dose every 4 weeks) significantly reduces severity.
GLP-1 Side Effects Compared
GLP-1 Side Effects: Retatrutide, Tirzepatide & Semaglutide
GLP-1 medications share a core side effect profile driven by how they slow gastric emptying and reduce appetite. Semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide all cause nausea, diarrhea, and vomiting at different rates. Retatrutide is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, it showed up to 24% weight loss, with nausea of 45% at 12 mg and 17% to 60% at 8 mg depending on the starting dose. This guide covers the full comparison.
45%
Nausea at 12 mg (Phase 2)
4-8 wks
Until Symptoms Improve
3
Receptor Targets
Phase 3
Clinical Trials
What Makes Retatrutide Different?
GLP-1
Reduces appetite, slows gastric emptying
GIP
Enhances insulin, improves fat metabolism
Glucagon
Increases energy expenditure, burns fat
Most Common Side Effects
Based on Phase 2 clinical trial data (published in NEJM, 2023), retatrutide's side effects are primarily gastrointestinal, similar to other GLP-1 agonists but with some differences due to the glucagon component.
💡 Note: These rates come from the Phase 2 obesity trial (338 participants, 48 weeks), as posted on ClinicalTrials.gov (NCT04881760); retatrutide has no FDA label. *The 4 mg and 8 mg columns combine the groups that started at 2 mg and at 4 mg, the same grouping the NEJM paper (Jastreboff et al., 2023) used for efficacy; ClinicalTrials.gov reports each starting-dose group separately. The starting dose mattered: at 8 mg, nausea affected 17% of people who started at 2 mg but 60% of those who started at 4 mg. The 12mg dose showed the highest efficacy (24.2% weight loss). In Phase 3, nausea affected 28.6%, 38.4% and 42.4% at 4, 9 and 12 mg versus 14.8% on placebo in TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes), and 14%, 21% and 28% versus 8% in TRIUMPH-2 (adults with obesity and type 2 diabetes; Lancet, 2026). TRIUMPH-1 also recorded dysesthesia (abnormal or unpleasant skin sensations) in 5.1%, 12.3% and 12.5% at 4, 9 and 12 mg versus 0.9% on placebo.
Why Retatrutide Side Effects May Differ
The glucagon receptor component adds unique considerations:
Increased Thermogenesis
Glucagon activation increases energy expenditure, which may cause slight increases in heart rate or body temperature in some patients.
Blood Sugar Effects
Glucagon can raise blood sugar, but the GLP-1/GIP components counterbalance this. Net effect is improved glucose control.
Triple Synergy
The three receptors work together for greater weight loss, but the GI effects from GLP-1 remain the dominant side effect source.
Liver Fat Reduction
Glucagon helps mobilize liver fat, potentially reducing fatty liver disease. This is a beneficial "side effect."
When Do Side Effects Improve?
Retatrutide side effects follow a predictable pattern tied to dose escalation:
Week 1-2
Side effects most noticeable during initial dose and escalation.
Week 3-4
Body begins adapting; symptoms start to decrease.
Week 6+
Most patients report significant improvement or resolution.
Dose Escalation
Temporary return of symptoms, usually milder than initial onset.
💡 Pro tip: Retatrutide uses monthly dose escalation in trials: the Phase 2 12 mg group stepped 2, 4, 8, then 12 mg every 4 weeks, reaching the top dose after about 12 weeks. Starting low and stepping up gradually helps minimize side effects while reaching target doses. See the retatrutide dosage chart for the full escalation timeline.
How to Manage Side Effects
These are the same approaches that work for tirzepatide and semaglutide. For those who continue to struggle despite dietary changes, split dosing (microdosing) is a strategy some users explore to reduce peak drug concentrations and lower GI side effect intensity:
NAUSEA
- Eat smaller, more frequent meals
- Avoid fatty, greasy, or fried foods
- Stop eating when you feel full
- Ginger tea or ginger supplements
- Don't lie down right after eating
DIARRHEA
- Avoid high-fat foods
- Limit artificial sweeteners
- Stay well-hydrated
- Consider probiotics
CONSTIPATION
- Increase fiber intake gradually
- Drink 8+ glasses of water daily
- Consider a fiber supplement
- Regular physical activity
GENERAL TIPS
- Follow the dose escalation schedule
- Track symptoms to identify triggers
- Stay hydrated (especially important)
- Communicate with your provider
Serious Side Effects (From Trial Data)
⚠️ Based on Phase 2 data, watch for these serious effects:
Pancreatitis
- Severe, persistent abdominal pain
- Pain radiating to back
- Nausea/vomiting that won't stop
Gallbladder Issues
- Upper right abdominal pain
- Fever
- Jaundice (yellowing)
Allergic Reactions
- Difficulty breathing
- Severe rash
- Swelling of face/throat
Hypoglycemia Risk
- If using with insulin/sulfonylureas
- Shakiness, sweating, confusion
- Monitor blood sugar closely
How Retatrutide Side Effects Compare to Other GLP-1 Medications
Comparing retatrutide to tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) shows the trade-offs, though the numbers come from separate trials rather than a head-to-head comparison.
Semaglutide: Wegovy 2.4 mg (prescribing information, section 6.1 Table 3). Tirzepatide: Zepbound 5 to 15 mg (prescribing information, section 6.1 Table 1). Retatrutide: 12 mg group of the Phase 2 obesity trial (ClinicalTrials.gov NCT04881760); retatrutide has no FDA label, so these are trial data. The three come from separate trials with different populations, durations and placebo rates, so this is not a head-to-head comparison.
Retatrutide
Highest efficacy: 24.2% weight loss at 48 weeks in Phase 2; in TRIUMPH-1, 12 mg reached 25.0% at 80 weeks (treatment-regimen estimand; 28.3% by the efficacy estimand). Glucagon adds thermogenesis and liver fat reduction. Nausea at 12 mg was 45% in the small Phase 2 trial, 42.4% in Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes) and 28% in Phase 3 TRIUMPH-2 (adults with obesity and type 2 diabetes); no head-to-head results have been published (a retatrutide vs tirzepatide trial, TRIUMPH-5, is still running).
Tirzepatide
Nausea 25% to 29% across Zepbound 5 to 15 mg versus 8% on placebo (prescribing information, pooled SURMOUNT-1 and SURMOUNT-2). FDA approved, widely available.
Semaglutide
Diarrhea 30% and constipation 24% at Wegovy 2.4 mg, though its placebo rates were also higher (16% and 11%), so cross-trial ranking is unreliable. Most established safety data. Only option with an oral form (the Ozempic and Rybelsus tablets for diabetes, and the Wegovy pill for weight).
Related guides: Tirzepatide Side Effects · Semaglutide Side Effects
Frequently Asked Questions
Is retatrutide FDA approved?
Not yet. Retatrutide is investigational and not FDA-approved as of October 2026; see our retatrutide FDA timeline for the expected window. The FDA states it cannot be used in compounding under federal law and treats products sold "for research purposes" as illegally sold unapproved drugs, so in the US, lawful access is limited to a clinical trial or Lilly's expanded access program (ClinicalTrials.gov NCT07629401), which a doctor must request, for adults with a BMI of 35 or more whose obesity has not responded to the highest available dose of current weight-loss treatment, who have two or more serious obesity-related complications, and who cannot join a trial.
Are retatrutide side effects worse than tirzepatide?
It depends on the trial. In retatrutide's small Phase 2 trial (62 people at 12 mg), nausea was 45% and diarrhea 15% at 12 mg. In Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes), nausea was 42.4% and diarrhea 32.0% at 12 mg. In Phase 3 TRIUMPH-2 (adults with obesity and type 2 diabetes, 286 at 12 mg), nausea was 28% and diarrhea 34% at 12 mg. Zepbound's label gives nausea of 25-29% and diarrhea of 19-23% across its doses. These are separate trials with different populations, and no head-to-head results have been published (a retatrutide vs tirzepatide trial, TRIUMPH-5, is still running), so the comparison is indicative only.
Does the glucagon component cause different side effects?
The glucagon component may cause slight increases in heart rate and affects liver fat metabolism. However, the dominant side effects (nausea, diarrhea) come from the GLP-1 component, similar to other medications.
How long do retatrutide side effects last?
Based on clinical trial data, most patients see improvement within 4-8 weeks. The gradual dose escalation (a step every 4 weeks, reaching 12 mg after about 12 weeks in the Phase 2 trial) helps minimize side effects.
Bottom Line
Here's what the data tells us:
- GI side effects dominate: nausea, diarrhea, vomiting, constipation
- Higher efficacy = slightly higher side effects at maximum doses
- Glucagon adds benefits: liver fat reduction, increased energy expenditure
- Slow escalation helps: stepping up every 4 weeks (about 12 weeks to reach 12 mg) minimizes symptoms
- Still investigational: not FDA-approved as of October 2026; Phase 3 trials are still running
Sources
- Retatrutide Phase 2 Trial (Jastreboff et al., NEJM 2023)
- TRIUMPH-1 Phase 3 trial (Jastreboff et al., N Engl J Med, 2026; PMID 42814954; adults with obesity or overweight without diabetes; ClinicalTrials.gov NCT05929066)
- Retatrutide Phase 2 posted results (ClinicalTrials.gov NCT04881760, adverse events table)
- TRIUMPH-2 Phase 3 trial (The Lancet, 2026; adults with obesity and type 2 diabetes)
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026; retatrutide cannot be used in compounding)
- Zepbound Prescribing Information, Eli Lilly (section 6.1 Table 1, for the comparison table)
- Wegovy Prescribing Information, Novo Nordisk (section 6.1 Table 3, for the comparison table)
- Eli Lilly Medical Information: TRIUMPH-1 results (TRIUMPH-1 adverse-event table in adults with obesity or overweight without type 2 diabetes, citing the NEJM paper)
- ClinicalTrials.gov
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Always consult with a qualified healthcare provider before starting or changing any medication.